Possible association of β- and β-adrenergic receptor gene polymorphisms with susceptibility to breast cancer by unknown
Primary research
Possible association of β2- and β3-adrenergic receptor gene
polymorphisms with susceptibility to breast cancer
Xin-En Huang*†, Nobuyuki Hamajima*, Toshiko Saito*, Keitaro Matsuo*, Mitsuhiro Mizutani‡, 
Hiroji Iwata‡, Takuji Iwase‡, Shigeto Miura‡, Tsutomu Mizuno‡, Shinkan Tokudome† and Kazuo Tajima*
*Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
†Department of Public Health, Medical School, Nagoya City University, Nagoya, Japan
‡Department of Breast Surgery, Department of Clinical Laboratories, Aichi Cancer Center Hospital, Nagoya, Japan
Correspondence: Dr Nobuyuki Hamajima, Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden, 
Chikusa-ku, Nagoya 464-8681, Japan. Tel: +81 52 762 6111; fax: +81 52 763 5233; e-mail: nhamajim@aichi-cc.pref.aichi.jp
Introduction
The incidence of breast cancer has increased greatly in
Japan over the past 2 decades [1], and it has been esti-
mated that breast cancer would become the most
common malignant disease in Japanese females by the
year 2000 [2]. One of the main risk factors for breast
cancer in menopausal women is obesity [3,4]. The
increased amount of adipose tissue after menopause is
considered to elevate estradiol production, which in turn
increases the risk for breast cancer. Thus, genetic traits
that are related to obesity may influence the risk of post-
menopausal breast cancer in an indirect manner.
ADRB2 = β2-adrenergic receptor; ADRB3 = β3-adrenergic receptor; BMI = body mass index; CI = confidence interval; Glu = glutamic acid; OR =
odds ratio; PCR = polymerase chain reaction.
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Abstract
Background: The involvement of β2-adrenergic receptor (ADRB2) and β3-adrenergic receptor
(ADRB3) in both adipocyte lipolysis and thermogenic activity suggests that polymorphisms in the
encoding genes might be linked with interindividual variation in obesity, an important risk factor for
postmenopausal breast cancer. In order to examine the hypothesis that genetic variations in ADRB2
and ADRB3 represent interindividual susceptibility factors for obesity and breast cancer, we
conducted a hospital-based, case–control study in the Aichi Cancer Center, Japan.
Methods: A self-administered questionnaire was given to 200 breast cancer patients and 182 control
individuals, and pertinent information on lifestyle, family history and reproduction was collected.
ADRB2 and ADRB3 genotypes were determined by polymerase chain reaction (PCR) restriction
fragment length polymorphism assessment.
Results: Twenty-five (12.4%) breast cancer patients and 32 (17.6%) control individuals were found to
bear a glutamic acid (Glu) allele for the ADRB2 gene (odds ratio [OR] 0.67, 95% confidence interval
[CI] 0.38–1.18), and 60 (30.0%) breast cancer patients and 61 (33.5%) control individuals were
found to bear an Arg allele for the ADRB3 gene (OR 0.85, 95% CI 0.55–1.31). A significantly lower
risk was observed in those who carried the Glu ADRB2 allele and who reported first childbirth when
they were younger than 25 years (OR 0.35, 95% CI 0.13–0.99).
Conclusion: A potential association may exist between risk of breast cancer and polymorphisms in the
ADRB2 and ADRB3 genes; further studies in larger samples and/or in different ethnic groups are
warranted to investigate this potential association.
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It is now known that the adrenergic system plays a key role
in regulating energy balance through both thermogenesis
and lipid mobilization from brown or white adipose tissues
[5,6], and that human fat cells are equipped with adrenergic
receptors (adrenoceptors) β1, β2 (ADRB2) and β3
(ADRB3). The degree of affinity for adrenaline (epinephrine)
is β2 > β1 > β3, and for noradrenaline (norephinephrine) it is
β1 ≥ β2 > β3. The genes encoding ADRB2 and ADRB3,
which have been cloned from humans [7–9], have therefore
attracted much research attention with regard to their
impact on obesity and obesity-related health problems.
Among these adrenergic receptors, ADRB2 appears to be
the most effective regarding the mobilization of lipids,
especially from abdominal subcutaneous adipose tissues
[10,11]. An epidemiological study [12] revealed a marked
link between obesity and a polymorphism in codon 27 of
the ADRB2 gene that features a replacement of glutamine
by glutamic acid (Gln27→Glu). However, doubts have
also been cast on the role of this polymorphism in obesity
in German [13] and Japanese [14] women. A French
study [15] further pointed out that only in those with a
sedentary lifestyle is there an association.
A missense mutation in codon 64 of the ADRB3 gene that
results in substitution of tryptophan by arginine
(Trp64→Arg) in the first intracellular loop of the receptor
protein has also been reported in various ethnic groups,
including Japanese [16]. Increased body mass index
(BMI), a broadly used index of obesity, has been demon-
strated in Japanese Arg allele carriers [17]. A review [11]
identified a link between obesity and the Trp64→Arg poly-
morphism in 13 studies, but not in 15. Therefore, it is not
possible to draw firm conclusions.
To our knowledge, few studies have been conducted to
investigate the combined effect of polymorphisms in codon
27 of ADRB2 and codon 64 of ADRB3 on female obesity
and/or breast cancer. This combined effect more closely
resembles the real physiological status. In the present
study, associations with the Gln27→Glu polymorphism in
the ADRB2 gene and the Trp64→Arg polymorphism in the
ADRB3 gene were examined, both in premenopausal and
in postmenopausal Japanese women. Although obesity is
not a risk factor for premenopausal breast cancer, associa-
tions in premonopausal women were examined for compar-
ison with findings in postmenopausal women. This
exploratory analysis was expected to provide some clues
for future investigations, and so the findings should be con-
firmed by studies with larger sample sizes and/or with
samples from different ethnic groups.
Patients and methods
Study population
Between March 1999 and April 2000, staff from the Divi-
sion of Epidemiology and Prevention interviewed 247
female patients, all of whom had had breast cancer con-
firmed by histopathology analysis at Aichi Cancer Center
Hospital. Four patients expressed anxiety regarding genetic
testing; the remaining 243 patients were enrolled. Another
two patients refused to participate after enrollment. The
participation rate was thus 98% (241/247). After written
informed consent had been obtained, a self-administered
questionnaire was given and 7 ml peripheral blood was
taken. Three DNA samples were not available; one from a
hepatitis C virus carrier whose blood sample was not
stored, and two due to the failure of DNA extraction. After
excluding two patients who were younger than 30 or older
than 70 years, and 36 who had been diagnosed 5 years
before enrollment, 200 patients were recruited.
The control individuals were 182 female noncancer out-
patients who visited Aichi Cancer Center Hospital for an
annual health check up, mainly at the Departments of Gas-
troenterology, Breast Surgery and Gynecology, during the
same period. The study was approved by the Ethics Com-
mittee of Aichi Cancer Center Hospital (approval no 12-20).
Epidemiological investigation
In the self-administered questionnaire, information was
requested on demography, past personal history of
disease, history of disease in first-degree relatives,
smoking and drinking habits, beverage and food intake,
and reproductive history before the appearance of symp-
toms. An interviewer checked all written responses in
order to ensure that there were no unanswered questions
at the time of questionnaire collection.
Genetic analyses
Genomic DNA was isolated from the buffy-coat fraction of
each blood sample, using a QIAamp DNA Mini Kit
(Qiagen Incorporated, Valencia, CA, USA).
PCR amplification of the ADRB2 gene was conducted
using the following primers [12]: 5′-GAA TGA GGC TTC
CAG GCG TC-3′; and 5′-GGC CCA TGA CCA GAT
CAG CA-3′. Aliquots of 30–100 ng genomic DNA were
mixed with 25 µl reaction liquid containing 0.15 mmol/l
dNTPs, 12.5 pmol of each primer, 0.5 units of AmpliTaq
Gold, 2.5 µl GeneAmp 10 × PCR buffer with 15 mmol/l
MgCl2 (Perkin-Elmer Corporation, Foster City, CA, USA),
and 1 µl glycerol. Amplification conditions were set as
follows: a 10-min initial denaturation at 94°C, followed by
30 cycles at 95°C for 1 min, 63°C for 1 min and 72°C for
1 min; final extension was conducted at 72°C for 5 min.
The amplified products were directly incubated with 1 unit
of Fnu4HI (New England Biolab Incorporated, Beverly,
MA, USA) for 3 h at 37°C, and digested fragments were
visualized on 2.5% agarose gels with ethidium bromide
staining. Genotyping was as follows: 174, 97, 55 and
27 bp for the Gln allele; and 229, 97 and 27 bp for the
Glu allele.
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PCR amplification of the ADRB3 gene was conducted
using the following primers [18]: 5′-CAA TAC CGC CAA
CAC CAG TGG G-3′; and 5′-GGT CAT GGT CTG GAG
TCT CG-3′. Each 25-µl reaction mixture contained
30–100 ng genomic DNA, 25 pmol of each primer,
15 mmol/l MgCl2 (Perkin-Elmer Corporation), 0.15 mmol/l
dNTPs, 0.5 units of Takara Taq, and 1 µl glycerol. The
reactions were conducted with incubation at 95°C for
10 min, followed by 30 cycles at 95°C for 30 s, 60°C for
30 s and 72°C for 30 s. PCR products were directly
digested by adding 15 units of MspI enzyme (New
England Biolab Incorporated) for 8 h at 37°C, and the
fragments obtained were separated on a 4% agarose gel
and visualized under ultraviolet light after staining with
ethidium bromide. Genotypes were defined as follows:
99,54-bp for the Trp allele; and 70,54,29-bp for the Arg
allele.
Statistical methods
The ORs and 95% CIs were calculated using an uncondi-
tional logistic regression model, using software from the
SAS statistical program package [19]. Interaction terms
between genotypes and risk factors were also examined by
the logistic model. Differences between two means were
assessed using Student’s t-test. The null hypothesis was
rejected at the 5% level (P < 0.05), and all reported P
values were two-sided. The genotype frequencies in Japan-
ese persons have been reported to be approximately 19%
for 27Glu of ADRB2 [20] and approximately 30% for 64Arg
of ADRB3 [21]. As estimated using the ‘sampsi’ command
of the Stata statistical software, release 6 [22], with these
genetic frequencies and with 200 cases and 182 control
individuals, the statistical power to detect ORs 2 and 0.5
would be as follows: 80.7 and 52.8% for ADRB2, respec-
tively; and 88.6 and 78.1% for ADRB3, respectively.
Results
Characteristics of all breast cancer patients and control
individuals are summarized in Table 1. Premenopausal
women constituted 54.2% of cases and 52.2% of control
individuals. Participants with a positive family history of
breast cancer, defined by breast cancer history in their
mother and/or sister(s), made up 12.4% of the cases and
2.2% of the control individuals.
Table 2 shows genotypes and allele frequencies for
Gln27→Glu and Trp64→Arg polymorphisms of ADRB2
and ADRB3, respectively. The Glu allele frequency was
6.7% for cases and 9.1% for control individuals, and
homozygotes for Glu were rare in both groups; the Arg
allele frequency was 16.0% for cases and 17.6% for
control individuals. Because associations of Gln27→Glu
and Trp64→Arg polymorphisms with obesity have recently
been attracting research attention, the BMI for the control
group was compared among genotypes of ADRB2 or
ADRB3. No differences were found in mean BMI between
those who harbored Gln/Gln alleles (BMI 22.2 ± 2.9 kg/m2)
and those with at least one Glu allele (BMI
22.3 ± 3.1 kg/m2; P = 0.426 by t-test). BMIs for those with
the Trp/Trp genotype and those with at least one Arg allele
were 22.3 ± 3.0 kg/m2 and 22.1 ± 2.8 kg/m2, respectively
(P = 0.603 by t-test).
Table 3 shows the crude and age-adjusted ORs for the
genotypes of ADRB2 and ADRB3. Regarding the
Gln27→Glu polymorphism of the ADRB2 gene, those
with a Glu allele had a decreased risk for breast cancer as
compared with those with a Gln/Gln genotype (crude OR
0.67, 95% CI 0.38–1.18; age-adjusted OR 0.65, 95% CI
0.37–1.16). Because this is a case–control study with
prevalent cases, the OR was also examined separately
according to the period between diagnosis and enroll-
ment. The OR for those who had been enrolled for less
than 3 years was 0.68 (95% CI 0.35–1.35), and for those
who had been enrolled within 3–4 years the OR was 0.65
(95% CI 0.31–1.36). Statistically significant differences in
crude and age-adjusted ORs were not observed between
premenopausal and postmenopausal women. Accord-
ingly, further subgroup analyses were conducted, regard-
less of menopausal status. No significant differences in
ORs were found for age at menarche, BMI and breast
cancer family history. However, crude and age-adjusted
ORs were significantly lower in those who reported first
childbirth at younger than 25 years than in those who
Table 1
Characteristics of patients and control individuals
Control
Characteristics Patients (n [%]) individuals (n [%])
Age at diagnosis or check up (years)
30–39 18 (9.0) 14 (7.7)
40–49 72 (36.3) 39 (21.4)
50–59 69 (34.3) 71 (39.0)
60–69 41 (20.4) 58 (31.9)
Age at menarche (years)
–13 92 (46.0) 89 (48.9)
14–15 84 (42.0) 65 (35.7)
16+ 23 (11.5) 28 (15.4)
No recall 1 (0.5) 0 (0.0)
Menopause
Premenopausal 108 (54.2) 95 (52.2) 
Postmenopausal 92 (45.8) 87 (47.8)
Body mass index
<20 46 (23.0) 42 (23.1)
20–24 108 (54.0) 93 (51.1)
≥24 46 (23.0) 47 (25.8)
Breast cancer family history, in mother and/or sister(s)
No 175 (87.6) 178 (97.8)
Yes 25 (12.4) 4 (2.2)
The total number of cases was 200, and that of control individuals was
182.
reported first childbirth when they were older than
25 years (crude OR 0.35, 95% CI 0.13–0.99; age-
adjusted OR 0.34, 95% CI 0.12–0.97). The interaction
term between the genotype and age at first childbirth esti-
mated by a case-only study [23] was 0.40 (95% CI










Genotypes and allele frequencies for the ADRB2 and ADRB3 genes among all study subjects
Mean ± SD BMI (kg/m2)
of subgrouped 
Genotypes and allele frequencies Patients (n [%]) Control individuals (n [%]) control individuals
Genotypes of ADRB2
Gln/Gln 175 (87.6) 150 (82.4) 22.2 ± 2.9*
Gln/Glu 23 (11.4) 31 (17.0)
Glu/Glu 2 (1.0) 1 (0.6)
Gln/Glu and Glu/Glu 22.3 ± 3.1*
Allele frequency of ADRB2
Gln 373 (93.3) 331 (90.9) –
Glu 27 (6.7) 33 (9.1) –
Genotypes of ADRB3
Trp/Trp 140 (70.0) 121 (66.5) 22.3 ± 3.0†
Trp/Arg 56 (28.0) 58 (31.9)
Arg/Arg 4 (2.0) 3 (1.6)
Trp/Arg and Arg/Arg 22.1 ± 2.8†
Allele frequency of ADRB3
Trp 336 (84.0) 300 (82.4) –
Arg 64 (16.0) 64 (17.6) –
The total number of cases was 200, and that of control individuals was 182. *P = 0.426, †P = 0.603 (by t-test).
Table 3
ORs and 95% CIs for ADRB2 and ADRB3 genes
ADRB2 gene ADRB3 gene
/Glu versus /Glu versus /Arg versus /Arg versus 
Control Gln/Gln Gln/Gln OR (95% CI) Trp/Trp Trp/Trp OR (95% CI) 
Subjects Patients individuals OR (95% CI) adjusted for age OR (95% CI) adjusted for age
All subjects 200 182 0.67 (0.38–1.18) 0.65 (0.37–1.16) 0.85 (0.55–1.31) 0.83 (0.54–1.29)
Interval after diagnosis
< 3 years 110 182 0.68 (0.35–1.35) 0.67 (0.34–1.33) 0.81 (0.49–1.36) 0.80 (0.48–1.34)
3–4 years 90 182 0.65 (0.31–1.36) 0.65 (0.31–1.38) 0.90 (0.52–1.54) 0.89 (0.51–1.55)
Menopause
Premenopausal 109 95 0.72 (0.32–1.65) 0.65 (0.28–1.51) 0.75 (0.42–1.35) 0.82 (0.45–1.48)
Postmenopausal 91 87 0.63 (0.29–1.38) 0.58 (0.26–1.28) 0.98 (0.51–1.87) 0.93 (0.48–1.80)
Body mass index
< 22 103 94 0.60 (0.27–1.33) 0.54 (0.24–1.25) 0.97 (0.53–1.77) 0.92 (0.49–1.72)
≥22 97 88 0.75 (0.34–1.69) 0.76 (0.34–1.69) 0.75 (0.40–1.38) 0.74 (0.40–1.38)
Menarche
<14 years 92 89 0.79 (0.34–1.88) 0.78 (0.33–1.86) 0.82 (0.44–1.53) 0.83 (0.44–1.57)
≥14 years* 108 93 0.59 (0.28–1.25) 0.54 (0.25–1.18) 0.89 (0.49–1.62) 0.81 (0.44–1.50)
First birth
< 25 years 84 67 0.35 (0.13–0.99) 0.34 (0.12–0.97) 0.92 (0.46–1.83) 0.95 (0.47–1.93)
≥25 years or no birth 116 115 0.93 (0.47–1.85) 0.93 (0.46–1.85) 0.81 (0.46–1.41) 0.78 (0.44–1.36)
Family history of breast cancer, in mother or sister(s)
No 175 178 0.67 (0.37–1.23) 0.65 (0.36–1.2) 0.77 (0.49–1.20) 0.75 (0.47–1.18)
Yes 25 4 0.19 (0.02–1.78) 0.16 (0.01–1.78) 2.36 (0.21–25.9) 2.30 (0.20–26.6)
*One missing value in the case group. /Arg, a combination of Trp/Arg and Arg/Arg; /Glu, a combination of Gln/Glu and Glu/Glu.
With regard to the Trp64→Arg polymorphism in the
ADRB3 gene, those who harboured at least one Arg allele
had a crude OR of 0.85 (95% CI 0.55–1.31) relative to
those who were homozygous for Trp. The OR for post-
menopausal women was similar to that for their pre-
menopausal counterparts. Substantial differences in ORs
were also not observed for variations in the period
between diagnosis and enrollment, as well as BMI, first
menarche, childbirth and family history of breast cancer.
The ORs for combined impact of gene polymorphisms in
ADRB2 and ADRB3 on risk of breast cancer, together
with the mean BMI of control individuals, are presented in
Table 4. Relative to individuals who were homozygous for
the Gln allele of ADRB2 and for the Trp allele of ADRB3,
the other three groups demonstrated a decreased risk for
breast cancer; those who simultaneously carried the
ADRB2 Glu and ADRB3 Arg alleles had the most
markedly reduced risk (OR 0.37, 95% CI 0.11–1.23), but
none of these decreases were statistically significant. It
was also found that the average BMIs among the four
genotype groups were very similar (all around 22.2 kg/m2),
with standard deviations of approximately 3.0 kg/m2.
Discussion
Before the results are interpreted, several limitations of the
present study should be addressed. First, the study was a
case–control study with hospital control individuals, and
not a population-based one. However, we performed a val-
idation study in order to evaluate the impact of this, and
confirmed that lifestyle differences between Aichi Cancer
Center Hospital noncancer outpatients and the general
population in Nagoya were small [24]. The majority of the
control individuals visited Aichi Cancer Center Hospital
only for regular health check-ups. The allele frequencies
for both polymorphisms were similar to those reported in
other population-based Japanese studies [17,21,25]. The
average BMI of the control individuals was 22.3 kg/m2,
which is consistent with the BMI in other population-
based control groups [26]. Furthermore, the genotypes
were apparently not reasons for visiting the Aichi Cancer
Center Hospital. Thus, the assessment of the control
group in the present study is unlikely to have biased the
results. The second concern is recall bias. In the present
study all questionnaires were completed before genotyp-
ing; therefore, the information from the questionnaires and
data from genetic analyses were independent. Third, the
breast cancer patients were under treatment and/or follow
up (ie prevalent cases). However, the participation rate of
patients was 98%; the OR for those diagnosed within the
past 3 years was similar to the OR in those who had been
diagnosed more than 3 years previously, indicating that
the influence on prognosis was small.
In the present study, the major finding was that presence
of 27Glu in ADRB2 or 64Arg in ADRB3 was associated
with a decreased risk for breast cancer, especially when
combined. This decrease in risk was statistically signifi-
cant for those who simultaneously harboured 27Glu
ADRB2 and had given birth early in life, but was not signif-
icant for the following subgroups: premenopausal women,
postmenopausal women and women with a small BMI.
There did not appear to be any association of these two
polymorphisms, separate or combined, with BMI.
Since the present study did not support our hypothesis
that the alleles related to obesity increase postmenopausal
breast cancer risk, other possible explanations should be
considered. First, the process of fat metabolism might be
far more complicated than can be accounted for by genetic
polymorphisms. Obesity is a combined consequence of
environment and host factors. The latter includes not only
genetic variations, but also psychological and pathophysio-
logical aspects that may cause interindividual differences in
energy intake, absorption, transportation, storage and
metabolism. All of these modifiers should be considered
when interpreting data regarding associations with genetic
polymorphisms. Second, a previous study [27] showed
that a full lipolytic response of fat cells can be obtained
when only a fraction of the β1 and β2 receptors are occu-
pied. Thus, the process of β-adrenergic receptor-mediated
lipolysis should also be further investigated.
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Table 4
ORs and 95% CIs for combinations of ADRB2 and ADRB3 genetic polymorphisms
Combined genotypes
Patients Control ORs for breast Age-adjusted ORs Mean BMI of control 
ADRB2 ADRB3 (n) individuals (n) cancer (95% CI) for breast cancer (95% CI) individuals ± SD
Gln/Gln Trp/Trp 119 98 1.00 1.00 22.3 ± 3.0
Gln/Gln /Arg 56 52 0.89 (0.56–1.41) 0.88 (0.55–1.41) 22.1 ± 2.8
/Glu Trp/Trp 21 23 0.75 (0.39–1.44) 0.76 (0.39–1.46) 22.4 ± 3.1
/Glu /Arg 4 9 0.37 (0.11–1.23) 0.32 (0.10–1.10) 22.2 ± 2.9
The total number of cases was 200, and that of control individuals was 182. /Arg, a combination of Trp/Arg and Arg/Arg; /Glu, a combination of
Gln/Glu and Glu/Glu.
Other findings were as follows. The preventive effect of
the 27Glu allele for ADRB2 was stronger than that of
64Arg for ADRB3, which is consistent with their affinities
for adrenaline and noradrenaline [28]. Furthermore, on the
basis of the estimated OR (0.75 for ADRB2 and 0.89 for
ARDB3) the effect was synergistic (OR = 0.37, which is
smaller than 0.75 × 0.89 = 0.67), and is biologically plau-
sible. The preventive effect of 27Glu ADRB2 was larger in
low-risk women, such as those with late menarche, early
childbirth, or low BMI. All of these features are characteris-
tic of Asian females. Thus, the present results indicate that
the mechanisms that underlie the preventive effects of
27Glu in ADRB2 and 64Arg in ADRB3 may not be related
to lipolytic and/or thermogenic activity, and other aspects
of these polymorphisms should be elucidated.
Conclusion
The present exploratory analysis suggests that an associ-
ation may exist between risk of breast cancer and poly-
morphisms in codon 27 of ADRB2 and 64 of ADRB3
genes; further studies in larger samples and/or in differ-
ent ethnic groups are warranted to investigate this poten-
tial association.
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